Wedbush began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The firm issued an outperform rating and a $40.00 price target on the stock.
Oruka Therapeutics Stock Performance
NASDAQ:ORKA opened at $24.99 on Wednesday. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.
Recommended Stories
- Five stocks we like better than Oruka Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
